Kenichiro Kuninobu, PhD

Nobu joined NIPRO in 2007 as a CMC scientist, and over the next three years, he launched two commercial products and was in charge of collaboration with Swiss global pharma for the US project. In April 2010, he was appointed to the corporate strategy position of NIPRO’s pharma division to lead the company’s reorganization. In June 2012, he was appointed to lead the company’s new manufacturing project from scratch in Vietnam. In 2016, he was co-appointed to a business development position. In 2019, he was assigned to lead the US regenerative advanced therapy project in collaboration with Yale University. His effort resulted in a successful pre-IND meeting with FDA in 2021. In 2022, he started a new career in FELIQS, a therapeutic start-up company co-founded with Dr.Kenichi Yamada, a professor at Kyushu University.​He holds a Master’s degree in Pharmaceutical Sciences from Kyushu University and a Ph.D. degree in Medical Science in Infection Research from Nagasaki University.